Vimarsana
Biggest News Aggregation in the World

Bio Lococyte News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bio Lococyte. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bio Lococyte Today - Breaking & Trending Today

FDA Grants Fast Track Designation to AVB-001 for R/R Platinum-Resistant Ovarian Cancer - Vimarsana News

FDA Grants Fast Track Designation to AVB-001 for R/R Platinum-Resistant Ovarian Cancer

Published: October 2, 2023

The FDA has granted fast track designation to AVB-001 for the treatment of adult patients with relapsed/refractory, platinum-resistant, high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.

Source: onclive.com
Related Topics:
Michael HeffernanBio LococyteBio IncAvenge BioBio Announces Successful CompletionFirst Dose Level CohortAvb 001 Ovarian CancerFast Track Designation
Avenge Bio Announces Closing of $45 Million Series A Financing - Vimarsana News

Avenge Bio Announces Closing of $45 Million Series A Financing

Published: January 5, 2022

/PRNewswire/ -- Avenge Bio, Inc., a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune...

Source: prnewswire.com
Related Topics:
Rock SpringsUnited StatesRice UniversityOmid VeisehScott MorensteinJosh RichardsonAmir JazaeriBio LococyteBen AskewMichael HeffernanDavid MelamedPaul WottonPrnewswire Avenge Bio IncUniversity Of Texas Md Anderson Cancer CenterDepartment Of Gynecologic OncologyBio IncRusso PartnersClinical ResearchPerceptive Xontogeny Venture FundGynecologic Cancer Immunotherapy ProgramLongitude CapitalRock Springs CapitalAvenge BioInvestigational New DrugChief Executive Officer